Literature DB >> 30882368

The use of biologics for immune modulation in allergic disease.

Willem van de Veen1,2, Mübeccel Akdis1.   

Abstract

The rising prevalence of allergies represents an increasing socioeconomic burden. A detailed understanding of the immunological mechanisms that underlie the development of allergic disease, as well as the processes that drive immune tolerance to allergens, will be instrumental in designing therapeutic strategies to treat and prevent allergic disease. Improved characterization of individual patients through the use of specific biomarkers and improved definitions of disease endotypes are paving the way for the use of targeted therapeutic approaches for personalized treatment. Allergen-specific immunotherapy and biologic therapies that target key molecules driving the Th2 response are already used in the clinic, and a wave of novel drug candidates are under development. In-depth analysis of the cells and tissues of patients treated with such targeted interventions provides a wealth of information on the mechanisms that drive allergies and tolerance to allergens. Here, we aim to deliver an overview of the current state of specific inhibitors used in the treatment of allergy, with a particular focus on asthma and atopic dermatitis, and provide insights into the roles of these molecules in immunological mechanisms of allergic disease.

Entities:  

Year:  2019        PMID: 30882368      PMCID: PMC6436858          DOI: 10.1172/JCI124607

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  141 in total

1.  Murine bone marrow-derived mast cells as potent producers of IL-9: costimulatory function of IL-10 and kit ligand in the presence of IL-1.

Authors:  M Stassen; M Arnold; L Hültner; C Müller; C Neudörfl; T Reineke; E Schmitt
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

2.  Human thymic stromal lymphopoietin preferentially stimulates myeloid cells.

Authors:  P A Reche; V Soumelis; D M Gorman; T Clifford; M Travis; S M Zurawski; J Johnston; Y J Liu; H Spits; R de Waal Malefyt; R A Kastelein; J F Bazan
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

3.  Functional expression of IL-9 receptor by human neutrophils from asthmatic donors: role in IL-8 release.

Authors:  S Abdelilah; K Latifa; N Esra; L Cameron; L Bouchaib; N Nicolaides; R Levitt; Q Hamid
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

4.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.

Authors:  L C Borish; H S Nelson; M J Lanz; L Claussen; J B Whitmore; J M Agosti; L Garrison
Journal:  Am J Respir Crit Care Med       Date:  1999-12       Impact factor: 21.405

5.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

Authors:  M J Leckie; A ten Brinke; J Khan; Z Diamant; B J O'Connor; C M Walls; A K Mathur; H C Cowley; K F Chung; R Djukanovic; T T Hansel; S T Holgate; P J Sterk; P J Barnes
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

6.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.

Authors:  L C Borish; H S Nelson; J Corren; G Bensch; W W Busse; J B Whitmore; J M Agosti
Journal:  J Allergy Clin Immunol       Date:  2001-06       Impact factor: 10.793

7.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.

Authors:  M Solèr; J Matz; R Townley; R Buhl; J O'Brien; H Fox; J Thirlwell; N Gupta; G Della Cioppa
Journal:  Eur Respir J       Date:  2001-08       Impact factor: 16.671

8.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.

Authors:  W Busse; J Corren; B Q Lanier; M McAlary; A Fowler-Taylor; G D Cioppa; A van As; N Gupta
Journal:  J Allergy Clin Immunol       Date:  2001-08       Impact factor: 10.793

9.  Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Authors:  H Milgrom; W Berger; A Nayak; N Gupta; S Pollard; M McAlary; A F Taylor; P Rohane
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

10.  IL-9 expression by human eosinophils: regulation by IL-1beta and TNF-alpha.

Authors:  A S Gounni; E Nutku; L Koussih; F Aris; J Louahed; R C Levitt; N C Nicolaides; Q Hamid
Journal:  J Allergy Clin Immunol       Date:  2000-09       Impact factor: 10.793

View more
  10 in total

Review 1.  Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease.

Authors:  Archana Shankar; Jaclyn W McAlees; Ian P Lewkowich
Journal:  J Allergy Clin Immunol       Date:  2022-08       Impact factor: 14.290

2.  The Developmental Transcription Factor p63 Is Redeployed to Drive Allergic Skin Inflammation through Phosphorylation by p38α.

Authors:  Yanek Jiménez-Andrade; Kathryn R Hillette; Toshimi Yoshida; Mariko Kashiwagi; Min-Kyung Choo; Yinming Liang; Katia Georgopoulos; Jin Mo Park
Journal:  J Immunol       Date:  2022-05-27       Impact factor: 5.426

3.  Targeted deletion of Interleukin-3 results in asthma exacerbations.

Authors:  Julia Kölle; Theodor Zimmermann; Alexander Kiefer; Ralf J Rieker; Paraskevi Xepapadaki; Sebastian Zundler; Nikolaos G Papadopoulos; Susetta Finotto
Journal:  iScience       Date:  2022-05-23

4.  Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases.

Authors:  Rohit Gaurav; Jill A Poole
Journal:  J Asthma       Date:  2021-12-27

5.  Analysis of Galectin-Binding Receptors on B Cells.

Authors:  Asmi Chakraborty; Norhan B B Mohammed; Angela E Bernasconi; Charles J Dimitroff
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Immunological Outcomes of Allergen-Specific Immunotherapy in Food Allergy.

Authors:  Ann-Marie Malby Schoos; Dominique Bullens; Bo Lund Chawes; Joana Costa; Liselot De Vlieger; Audrey DunnGalvin; Michelle M Epstein; Johan Garssen; Christiane Hilger; Karen Knipping; Annette Kuehn; Dragan Mijakoski; Daniel Munblit; Nikita A Nekliudov; Cevdet Ozdemir; Karine Patient; Diego Peroni; Sasho Stoleski; Eva Stylianou; Mirjana Tukalj; Kitty Verhoeckx; Mihaela Zidarn; Willem van de Veen
Journal:  Front Immunol       Date:  2020-11-03       Impact factor: 7.561

Review 7.  Association Between Microbiota and Nasal Mucosal Diseases in terms of Immunity.

Authors:  Junhu Tai; Mun Soo Han; Jiwon Kwak; Tae Hoon Kim
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

8.  Expression of Helper and Regulatory T Cells in Atopic Dermatitis: A Meta-Analysis.

Authors:  Dao-Jun Zhang; Fei Hao; Tian Qian; Hai-Xing Cheng
Journal:  Front Pediatr       Date:  2022-04-01       Impact factor: 3.569

9.  Reduced expression of miR-146a in human bronchial epithelial cells alters neutrophil migration.

Authors:  Anet Kivihall; Alar Aab; Jerzy Soja; Krzysztof Sładek; Marek Sanak; Alan Altraja; Bogdan Jakiela; Grazyna Bochenek; Ana Rebane
Journal:  Clin Transl Allergy       Date:  2019-11-27       Impact factor: 5.871

Review 10.  Bioengineering of Virus-like Particles for the Prevention or Treatment of Allergic Diseases.

Authors:  Phornsiri Pechsrichuang; Supannika Namwongnao; Alain Jacquet
Journal:  Allergy Asthma Immunol Res       Date:  2021-01       Impact factor: 5.764

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.